Can osteosarcoma kill people in the early stages?

As we all know, osteosarcoma is malignant. Once you get the disease, your body and mind will suffer great damage. It develops rapidly, threatens life, is difficult to cure, and is prone to recurrence. Because the early symptoms are not obvious, patients are likely to miss the opportunity for treatment. Now let's talk about whether osteosarcoma will kill people in the early stage:

Early-stage osteosarcoma should be treated surgically whenever possible. Surgery must be radical resection to avoid local recurrence. Currently, limb salvage has become the main surgical procedure for osteosarcoma, but when limb salvage is not suitable or unconditional, amputation should be performed decisively. Chemotherapy is not necessary before surgery, but standardized chemotherapy must be performed after surgery.

The incidence of osteosarcoma is relatively high. Osteosarcoma is a highly malignant tumor. Before the 1970s, the mortality rate of the disease reached more than 90%, and the five-year survival rate was less than 10%. Now, after continuous efforts and research by bone tumor specialists, under active and correct treatment, the five-year survival rate of patients is about 70%. Our department has reached the top level in the country in the treatment of osteosarcoma, and is also at the leading level in the world. The survival period of bone cancer patients generally has three years of survival, five years of survival, and ten years of survival, which refers to survival for three years, five years, and more than ten years after surgery, respectively. The medical community has its corresponding cure standards for different degrees of cancer. Regarding the issue of patient survival, it also depends on the individual. Some people with better postoperative effects can live like normal people, and can live to 70, 80 years old or even older like normal people. For the treatment of cancer, the key lies in early detection and the patient's positive attitude.

However, due to the emergence of neoadjuvant chemotherapy, especially with adequate doses and reasonable regimens, the survival rate has been significantly improved. The efficacy of osteosarcoma is evaluated by the statistical 5-year survival rate. Under the most scientific and reasonable treatment, the 5-year survival rate of osteosarcoma can reach more than 70%, and patients who live for more than 5 years have a more than 90% chance of long-term survival. From our experience, osteosarcoma is most likely to recur and metastasize within 2 years after treatment. If there is no recurrence and metastasis within 2 years, it is basically possible to control it. The recurrence rate five years after surgery is relatively high. Regular follow-up and regular medication are required after surgery. The difficulty of tumor treatment lies in the easy recurrence and metastasis. Patients can take anti-cancer Chinese patent medicine oral liquid, which is safe, inhibits and eliminates tumors while improving immunity, regulating internal balance, and fundamentally preventing recurrence and metastasis.

Some osteosarcoma patients fail to detect the disease after recurrence and miss the best time for treatment after recurrence, which leads to worsening of the disease. At this time, life may be in danger at any time. The treatment of osteosarcoma recurrence is the same as the treatment of osteosarcoma. It is important to take systematic treatment in the early stage and pay attention to the psychological care of patients with recurrence of osteosarcoma. However, early detection and timely treatment have greatly improved the survival rate of the disease. After treatment, as well as various immune factors from the body, life will be tenacious. However, if it is not treated, osteosarcoma cells will metastasize to the lungs, and life will be directly affected.